Abstract: Isolated polynucleotides encoding Macaca fascicularis CCL17 (CynoCCL17), polypeptides obtainable from expression of these polynucleotides, recombinant cells, and methods of use are disclosed.

Abstract: The present invention relates to amino acid sequences that are directed against (as defined herein) human cellular receptors for viruses and/or bacteria such as e.g. NANOBODIES specifically recognizing hCD4, hCXCR4, hCCR5, hTLR4, human alphaV integrin, human beta3 integrin, human beta1 integrin, human alpha2 integrin, hCD81, hSR-BI, hClaudin-1, hClaudin-6 and hClaudin-9, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. The amino acid sequences may be used to prevent human cell entry of HIV, HCV, adenoviruses, hantavirus, herpesvirus, echo-virus 1 and others.

Abstract: The present invention relates to a dosing regimen for use in the treatment of stroke. More particularly, the invention relates to the administration of two doses of anti-MAG antibodies for the treatment of ischemic and/or haemorrhagic stroke.

Abstract: Compositions and methods comprising proteins that bind specifically to adalimumab are disclosed herein. Adalimumab is a monoclonal antibody specific for the cytokine TNF-? and was developed to treat TNF-? mediated inflammatory diseases. In one aspect of the instant invention, the binding proteins are antibodies directed toward adalimumab. These antibodies, including binding fragments thereof, can be used in a clinical setting as well as for research and development. For example, these anti-adalimumab antibodies can be employed to neutralize adalimumab.

Abstract: Embodiments of the invention are related to a polypeptide comprising the amino acid sequence of a human IgE-Fc C?3-C?4, wherein said C?3-C?4 starts at amino acid 328 and ends at amino acid 547 of said IgE-Fc, and wherein C 328 is A and K 367 is C. Other embodiments concern a second polypeptide comprising the amino acid sequence of a human Fc?RI? extracellular region, wherein said extracellular region starts at amino acid 1 and ends at amino acid 176 of said Fc?RI?. Still other embodiments are related to a method of identifying a compound that inhibits the binding of an IgE-Fc to a Fc?RI?, said method comprising: contacting the polypeptide, wherein said IgE-Fc C?3-C?4 sequence is labeled with a fluorophore, and the second polypeptide, with a test compound; and determining whether binding of said polypeptide to said second polypeptide is decreased in the presence of said test compound.

Abstract: The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human CD20. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.

Abstract: Provided herein are glycovariant Fc fusion proteins having increased serum half lives. Also provided are methods for increasing the serum half life of an Fc fusion protein by introducing one or more non-endogenous glycosylation sites.

Abstract: A recombinant expression vector, comprising extracellular soluble domain genes of DLK1 and IgG antibody Fc domain genes, is constructed, and DLK1-Fc fusion protein is expressed and purified at 293E cell. The invention confirmed the efficacy as a drug for inhibiting cancer metastasis by confirming markedly reduced migration of cancer cells by DLK1-Fc fusion protein and also computing pharmacokinetic parameters. DLK1-Fc fusion protein has relatively higher stability than non-fusion protein, significantly reduces migration of various cancer cell lines, and provides superior cancer metastasis inhibition effect even at small concentration. Accordingly, DLK1-Fc fusion protein can be used efficaciously as an effective ingredient of a composition for inhibiting cancer metastasis.

Abstract: The present invention relates to target binding members (e.g., antibodies) that bind a specified epitope of human IL-25. The invention also relates to target binding members (e.g., antibodies) that comprise one or more humanized antibody VL domain sequences and bind IL-25. The invention further relates to compositions comprising target binding members (e.g., antibodies) that bind IL-25, methods of producing such target binding members, and uses of such target binding members for the treatment or prevention of diseases and conditions (e.g., asthma, inflammatory bowel disease).

Abstract: Transplacental enzyme replacement therapy (ERT) is disclosed for deficiency of a polypeptide such as a tissue-nonspecific alkaline phosphatase (TNSALP) by administering a pharmaceutical composition that comprises a water-soluble TNSALP portion, e.g., C-terminus-truncated TNSALP peptide-bonded to an IgG1 antibody Fc portion, to a pregnant animal whose fetus or embryo is in need of such therapy. Also contemplated is a method for treating a metabolic disorder, such as HPP, in a fetus or embryo where a fusion protein that comprises a Fc fragment of an IgG1 antibody peptide-bonded to TNSALP is administered to a pregnant mother. The protein crosses the placenta of the mother and enters the fetal blood stream. The protein is taken up into fetal tissue such that the TNSALP restores normal metabolic activity in the fetus.

Abstract: The present invention relates to a method of diagnosis and therapy of cancers expressing the HER2 receptor. The invention provides antibodies or fragments thereof that recognise an epitope of the HER2 receptor truncated form CTF-611, said epitope being defined by a sequence included in SEQ ID NO: 2, and that are capable of discriminating between CTF-611 and CTF-616 (represented by SEQ ID NO:7), preferably additionally capable of discriminating between CTF-611 and CTF-613 (represented by SEQ ID NO:6). The invention also provides a method of cancer diagnosis using the disclosed antibodies, which comprises the detection of the presence of the HER2 receptor truncated form consisting of the amino acid sequence SEQ ID NO: 1 in a patient sample.

Abstract: The present disclosure relates to antibodies directed to the tumor necrosis factor alpha (“TNF-?”) and uses of such antibodies, for example, to treat diseases associated with the activity and/or overproduction of TNF-?.

Abstract: The present invention relates to the provision of novel immunogens comprising an antigenic IgE peptide preferably linked to an immunogenic carrier, compositions comprising the immunogens, and methods for the prevention, treatment or alleviation of IgE-mediated disorders. The invention further relates to methods for production of these medicaments, immunogenic compositions and pharmaceutical compositing thereof and their use in medicine.

Abstract: The invention pertains to methods and compositions for treating medical disorders characterized by elevated levels or abnormal expression of TNF? by administering a TNF? antagonist, such as recombinant TNFR:Fc.

Abstract: The present invention is directed to novel polypeptide, designated in the present application as “UCP4” (SEQ ID NO: 1), having homology to certain human uncoupling proteins (“UCPs”) and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention, and methods for producing the polypeptides of the present invention.

Abstract: Isolated receptors, DNAs encoding such receptors, and pharmaceutical compositions made therefrom, are disclosed. The isolated receptors can be used to regulate an immune response. The receptors are also useful in screening for inhibitors thereof.

Abstract: A binding partner, especially an antibody fragment that specifically recognizes an antigen-antibody immune complex between anti-THC and THC (tetrahydrocannabinol), is disclosed. The binding partner facilitates a non-competitive homogenous immunoassay for detection of cannabis use. A test kit comprising the binding partner is also described. Preferably the immunoassay is applied for roadside testing of saliva from suspected drivers.

Abstract: A binding partner, especially an antibody fragment that specifically recognizes an antigen-antibody immune complex between anti-THC and THC (tetrahydrocannabinol), is disclosed. The binding partner facilitates a non-competitive homogenous immunoassay for detection of cannabis use. A test kit comprising the binding partner is also described. Preferably the immunoassay is applied for roadside testing of saliva from suspected drivers.

Abstract: The invention relates to binding compounds that specifically bind to human TSLPR, as well as uses thereof, e.g., in the treatment of inflammatory disorders.

Abstract: The invention provides antibodies, including chimeric human antibodies, recombinant antibodies, synthetic antibodies, and the nucleic acids encoding them, and methods for making and using these immunoglobulins. The invention provides recombinant and synthetic polypeptide and nucleic acid embodiments of these polypeptides and/or antibodies. The invention also provides polypeptides comprising, or consisting of, consensus human framework regions, or “Independently Consensused Frameworks (ICFs)”, nucleic acids encoding them, and libraries and kits comprising these ICFs and/or antibodies of the invention, individually and in combinatorial libraries and combinations.

Abstract: The invention pertains to methods and compositions for treating medical disorders characterized by elevated levels or abnormal expression of TNF? by administering a TNF? antagonist, such as recombinant TNFR:Fc.

Abstract: A method of treating an autoimmune disease comprising administering to a patient a therapeutically effective amount of a CD20-binding polypeptide composition comprising a combination of a modified heavy chain variable region polypeptide and a modified light chain variable region polypeptide. The combination can be (a) a modified 2B8 antibody heavy chain variable region polypeptide of SEQ ID NO: 48; and a modified 2B8 antibody light chain variable region polypeptide of SEQ ID NO: 49; or (b) a modified Leu16 antibody heavy chain variable region polypeptide of SEQ ID NO: 50; and a modified Leu16 antibody light chain variable region polypeptide of SEQ ID NO: 51.

Abstract: The present invention provides chimeric and humanized versions of anti-CD19 mouse monoclonal antibodies. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using therapeutic antibodies that bind to the human CD19 antigen and that may mediate ADCC, CDC, and/or apoptosis for the treatment of B cell diseases and disorders, such as, but not limited to, B cell malignancies, for the treatment and prevention of autoimmune disease, and for the treatment and prevention of graft-versus-host disease (GVHD), humoral rejection, and post-transplantation lymphoproliferative disorder in human transplant recipients.

Abstract: Disclosed is an isolated polynucleotide encoding a modified Fab' antibody, which includes an Fd chain and an L chain with the Fd chain including a CH1 region and the L chain including a CL region, wherein the modified Fab' antibody further includes a cysteine for binding to a fluorescent dye, and the polynucleotide includes an Fd chain coding region and an L chain coding region linked therebetween in a manner that will allow expression of the modified Fab' antibody. Also disclosed are an expression vector containin the isolated polynucleotide, an isolated transformed host cell containing the expression vector, and a cell culture including the transformed host cell.

Abstract: The present invention relates to antibodies, binding portions thereof, or probes that bind specifically to glucosyltransferase enzymes, and uses of these agents for detecting glucosyltransferase enzyme(s) in a sample and for diagnosing predisposition of a human child to early childhood caries. The present invention also relates to a kit for detecting a glucosyltransferase enzyme in an oral sample from an animal.

Abstract: The present invention relates to novel methods of identifying and producing an anti-platelet autoantibody. More preferably, the invention relates to identification and production of a human monoclonal anti-platelet autoantibody. Moreover, the invention relates to methods for treating or alleviating a disease, disorder or condition mediated by an anti-platelet autoantibody specifically binding with a platelet, or a component thereof, such as, but not limited to, idiopathic thrombocytopenic purpura, among others. Preferably, the antibody is an unglycosylated H44L4 Fab.

Abstract: The invention pertains to methods and compositions for treating medical disorders characterized by elevated levels or abnormal expression of TNF? by administering a TNF? antagonist, such as recombinant TNFR:Fc.

Abstract: This invention provides antibodies immunologically specific for human ARL-1 (also referred to AKR1B10), a species of the aldo-keto reductase superfamily of proteins. The invention also provides methods of making and methods of using said antibodies.

Abstract: Divalent antibody fragments are described, each of which has one or more interchain bridges containing a synthetic or naturally occurring polymer selected from a polyalkylene, polyakenylene, polyoxyalkylene or polysaccharide. Each bridge may be the residue of a homo- or heterobifunctional cross-linking reagent and serves to link two heavy chains in each antibody fragment via the sulphur atoms of cysteine residues present in the chains. Each fragment may be attached to one or more effector or reporter molecules, and is of use in therapy or diagnostics where it has markedly improved binding and/or pharmacokinetic properties when compared to other antibody fragments which have the same number and type of polymer molecules but in which the polymer molecules are randomly attached.

Abstract: A method to treat conditions associated with A? peptide activity both prophylactically and therapeutically is described. The method employs humanized antibody fragments that specifically bind human A? peptide between amino acid positions 13-28, wherein the antibody fragments are covalently attached to a polyethylene glycol (PEG) molecule.

Abstract: F(ab) fragments are isolated from an antibody containing source by contacting the antibody containing source with a papain-polyacrylamide matrix to produce F(ab) and F(c) fragments which are then passed through an antigen-polyacrylamide gel capable of attracting the F(ab) fragments. F(ab)2 fragments are obtained by contacting the antibody containing source with a pepsin-polyacrylamide matrix to produce F(ab)2 and F(c) fragments which are then passed through an antigen-polyacrylamide gel capable of attracting the F(ab)2 fragments. IgG antibodies are obtained by passing an antibody containing source through an antigen-polyacrylamide gel. These processes can be used to purify a wide variety of antibodies which can be used as therapeutic agents and as diagnostic agents. Antivenins produced by these processes have substantially reduced foreign protein levels and hence are less likely to produce immunogenic reactions.

Abstract: The invention pertains to methods and compositions for treating medical disorders characterized by elevated levels or abnormal expression of TNF? by administering a TNF? antagonist, such as recombinant TNFR:Fc.

Abstract: A human antibody or antigen-binding fragment of an antibody that specifically binds human CD20 and is capable of inducing complement dependent cytotoxicity (CDC), and is capable of increasing symptom free survival time between about 2-fold to about 9-fold or more, relative to control-treated animals in a mouse model of human lymphoma. The antibody or antigen-binding fragment thereof is useful in a therapeutic method for treating a CD20-mediated disease or condition, such as for example, non-Hodgkin's lymphoma, rheumatoid arthritis, systemic lupus erythematosus, Crohn's disease, chronic lymphocytic leukemia, and inflammatory diseases.

Abstract: A capturing molecule having not less than two domains specifically binding to different sites of a target substance, wherein the not less than two domains comprise (1) a first domain having a hypervariable loop structure at a binding site to the target substance, and (2) a second domain having no hypervariable loop structure at a binding site to the target substance.

Abstract: The present invention provides Chordin-Like (CHL) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing CHL polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with CHL polypeptides.

Abstract: The present invention relates to fusion proteins comprising a naturally occurring primate MAdCAM, wherein said naturally occurring primate MAdCAM binds ?4?7 integrin and has at least about 75% amino acid similarity to an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4 and SEQ ID NO:6.

Abstract: Methods for generating F(ab?)2 fragments from antibodies using thermolysin as well as F(ab?)2 fragments and compositions comprising F(ab?)2 fragments generated by the method are described.

Abstract: Methods for inhibiting osteoclastogenesis by administering a soluble RANK polypeptide are disclosed. Such methods can be used to treat a variety of different cancers, including bone cancer, multiple myeloma, melanoma, breast cancer, squamous cell carcinoma, lung cancer, prostate cancer, hematologic cancers, head and neck cancer and renal cancer.

Abstract: Monoclonal antibody that specifically binds to alpha-amylase and is useful for detecting weather damage (i.e. pre-harvest sprouting) in cereal grain.

Abstract: The present invention relates to a novel connective tissue growth factor-3 protein which is a member of the growth factor superfamily. In particular, isolated nucleic acid molecules are provided encoding the human connective tissue growth factor-3 protein. Connective tissue growth factor-3 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. Also provided are diagnostic and therapeutic methods for detecting and treating connective tissue related disorders.

Abstract: The invention includes compositions, kits and methods comprising a monoclonal antibody which shares key functional properties with the polyclonal antibodies which participate in the pathogenesis of heparin induced thrombocytopenia/thrombosis (HIT/HITT) in a mammal. The monoclonal antibody of the invention preferentially binds with a PF4/heparin complex relative to the binding of the antibody with PF4 or heparin alone. The monoclonal antibody of the invention also binds specifically with PF4 in a complex with other glycosaminoglycans besides heparin, and also activates platelets. The monoclonal antibody of the invention is useful in methods for diagnosing and treating HIT/HITT in a mammal. A humanized version of the monoclonal antibody of the invention is also included, along with a process for humanizing the monoclonal antibody of the invention.

Abstract: Novel Dkk and Dkk-related polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length Dkk and Dkk-related proteins, the invention further provides isolated fusion proteins, antigenic peptides and antibodies. The invention also provides Dkk and Dkk-related nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and n which a Dkk and Dkk-related gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.

Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those peptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

Abstract: The invention relates to: nucleic acid molecules encoding the light chain and heavy chain of feline immunoglobulin E (IgE), including species-specific regions of feline IgE; proteins encoded by the nucleic acid molecules; inhibitors to the nucleic acids and proteins; antibodies to the proteins; cells transformed with the nucleic acid molecules; assays employing the transformed cells, nucleic acids, antibodies and/or proteins or portions thereof; methods for treating IgE-mediated responses (ie. allergy) using the materials provided; methods for eliciting an immune response to IgE and kits containing the nucleic acid molecules, proteins or derivatives thereof (ie. antibodies).

Abstract: The present invention comprises a fusion molecule comprising a Fc? fragment sequence including functionally active CH2, CH3 and CH4 domains of the constant region of an IgE heavy chain (CH?2-CH?3-CH?4 sequence) linked at its C-terminus to the N-terminus of a second polypeptide including functionally active hinge, CH2 and CH3 domains of the constant region of an IgG1 heavy chain (?hinge-CH?2-CH?3 sequence), pharmaceutical compositions comprising the fusion molecule and methods of treatment using the fusion molecule.

Abstract: The present invention provides Chordin-Like (CHL) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing CHL polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with CHL polypeptides.

Abstract: A composition and method for treating a host having or at risk of infection by Bacillus anthracis using an affinity matured antibody or portion thereof derived from a monoclonal antibody.

Abstract: The invention relates to antibodies and immunologically active portions thereof that selectively bind a human Dickkopf-1 (Dkk-1) or Dkk-1-related polypeptide, and to compositions that contain such antibodies and/or immunologically active portions.

Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.